CD47 and neoplasm: To investigate the metabolic consequences of aptamer-siRNA therapy in tumor-infiltrating Treg cells, we performed targeted serum metabolomic profiling in mice bearing liver tumors and treated with saline, anti-PD-L1 aptamer, CD47 siRNA, or the aptamer-siRNA chimera.